These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29555189)

  • 1. Belimumab in systemic lupus erythematosus: Experience in clinical practice settings in a regional hospital.
    Riancho-Zarrabeitia L; Villa Blanco I; Santos-Gómez M; Aurrecoechea E
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 2):188-189. PubMed ID: 29555189
    [No Abstract]   [Full Text] [Related]  

  • 2. Alopecia areata in patients with systemic lupus erythematosus treated with belimumab: a plausible association.
    Shamriz O; Yahia SH; Ramot Y; Agmon-Levin N; Tal Y
    Lupus; 2020 Apr; 29(4):426-430. PubMed ID: 31924144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Belimumab in systemic lupus erythematosus: a guide for its use in the daily practice].
    Ramos-Casals M; Ruiz-Irastorza G; Jiménez-Alonso J; Khamashta MA;
    Rev Clin Esp (Barc); 2013; 213(1):66-7. PubMed ID: 23565550
    [No Abstract]   [Full Text] [Related]  

  • 4. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus.
    Parodis I; Gomez A; Emamikia S; Chatzidionysiou K
    Ann Rheum Dis; 2019 Jul; 78(7):1006-1007. PubMed ID: 30610063
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of Belimumab throughout 2 Consecutive Pregnancies in a Patient with Systemic Lupus Erythematosus.
    Kumthekar A; Danve A; Deodhar A
    J Rheumatol; 2017 Sep; 44(9):1416-1417. PubMed ID: 28864669
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab.
    Simonetta F; Allali D; Roux-Lombard P; Chizzolini C
    Joint Bone Spine; 2017 Mar; 84(2):235-236. PubMed ID: 27238199
    [No Abstract]   [Full Text] [Related]  

  • 7. Belimumab in systemic lupus erythematosus -- what can be learned from longterm observational studies?
    Bengtsson AA
    J Rheumatol; 2014 Feb; 41(2):192-3. PubMed ID: 24488851
    [No Abstract]   [Full Text] [Related]  

  • 8. A case of systemic lupus erythematosus/systemic sclerosis overlap syndrome successfully treated with belimumab.
    Hara M; Ogawa-Momohara M; Muro Y; Takeichi T; Akiyama M
    Eur J Dermatol; 2020 Oct; 30(5):615-617. PubMed ID: 32972910
    [No Abstract]   [Full Text] [Related]  

  • 9. Tapering belimumab in patients with systemic lupus erythematosus: a single-centre experience.
    Fredi M; Vojinovic T; Regola F; Babaglioni G; Bettoni D; Andreoli L; Tincani A; Franceschini F
    Rheumatology (Oxford); 2023 Feb; 62(2):e18-e20. PubMed ID: 35946521
    [No Abstract]   [Full Text] [Related]  

  • 10. [Lupus erythematosus treatment with belimumab in daily practice: Retrospective study of 15 patients].
    Garval E; Pennaforte JL; Jaussaud R; Servettaz A; Bernard P; Reguiai Z
    Ann Dermatol Venereol; 2018 Jan; 145(1):5-12. PubMed ID: 29113694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belimumab and the measurement of fatigue.
    Mazzoni D
    Ann Rheum Dis; 2015 Sep; 74(9):e53. PubMed ID: 25862616
    [No Abstract]   [Full Text] [Related]  

  • 12. [Belimumab--the biological drug for systemic lupus erythematosus: as discussed during the American College of Rheumatology (ACR) conference - 2012].
    Vadasz Z; Toubi E
    Harefuah; 2013 May; 152(5):304-6. PubMed ID: 23885457
    [No Abstract]   [Full Text] [Related]  

  • 13. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
    Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment.
    Jüptner M; Zeuner R; Schreiber S; Laudes M; Schröder JO
    Lupus; 2014 Apr; 23(4):428-30. PubMed ID: 24482144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to: 'belimumab and the measurement of fatigue' by Mazzoni.
    Strand V; Levy RA; Cervera R; Petri M
    Ann Rheum Dis; 2015 Sep; 74(9):e54. PubMed ID: 25990291
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of belimumab for the long-term maintenance therapy of thrombocytopenia in systemic lupus erythematosus.
    De Marchi G; Quartuccio L; Bond M; De Vita S
    Clin Exp Rheumatol; 2017; 35(6):1056. PubMed ID: 28770706
    [No Abstract]   [Full Text] [Related]  

  • 18. Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab.
    Sciascia S; Rubini E; Radin M; Cecchi I; Rossi D; Roccatello D
    Ann Rheum Dis; 2018 Nov; 77(11):1694-1695. PubMed ID: 29776976
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
    Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
    Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus.
    Chatzidionysiou K; Samoli E; Sfikakis PP; Tektonidou MG
    Ann Rheum Dis; 2020 Feb; 79(2):304-307. PubMed ID: 31712248
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.